genOway

The current genOway management committee is composed of six members: Alexandre Fraichard, Benjamin Bruneau, Cyrielle Chabrier, Florent Pons, Yacine Cherifi and Kader Thiam. We are the only company to invest heavily in this consulting activity, and each project feasibility analysis represents seven days of full-time equivalent activity of experts in bioinformatics, gene targeting, molecular biology, and cell biology. At genOway, we recognize the crucial role that preclinical research plays in the success of new therapies in clinical settings. Explore our service for creating genetically modified mouse, rat, and cell line models perfectly adapted to answer your scientific questions. Founded in 1999 by a four-member team around founder Alexandre Fraichard, genOway now has risen to become a leader in the field of customized, genetically modified (GM) mouse, rat and cell model creation. We have built a unique license portfolio for all technologies used, including exclusive licenses, which we are allowed to sublicense. Furthermore, our customers retain ownership of the deliverables and can patent the model developed. This provides you with cohorts ready for experimentation.